ClinicalTrials.gg
RecruitingNCT06367582Updated Sep 9, 2025

Spine Bone Cements Outcomes - Post Market Follow-up

An observational study in Vertebral Fracture, Compression Fracture and Osteoporotic Fractures, sponsored by Teknimed. Recruiting at 12 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Teknimed · Observational

From the registry’s dates

  • Started Sep 2019; still recruiting 7 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and performance of all TEKNIMED Spine range of products: SPINEFIX, HIGH V+, OPACITY+ and F20 bone cements and mixing and injection systems, and all their private labels.

TEKNIMED bone cements are legacy products, some marketed for more than 10 years. Their performance and safety have already been demonstrated by Post-Market Surveillance and previous clinical studies. The current Post-Market Clinical Follow-Up study aims to confirm these claims by collecting data in a "real-life" setting.

The study is a retrospective and prospective global, single arm, non-controlled, multicentric, prospective observational study. Patients will be followed as per local standard medical care of the sites.

Read the detailed description

It is admitted that:

  • Cementoplasty procedures such as vertebroplasty and kyphoplasty are recommended in the treatment of painful vertebral compression fractures, due to their efficiency and safety
  • These mini-invasive procedures, where bone cement is injected into a partially collapsed vertebral body, are used to reduce pain and to provide mechanical stability
  • In most patients, a rapid pain relief and an increase in mobility and quality of life are obtained
  • Serious complications from bone cements leaks and adjacent vertebral fractures can be observed but remain rather rare
  • The use of spinal cement in pedicle screw augmentation procedures can be relevant to increase the strength of the screw fixation in the bone, particularly in osteoporotic patients.

TEKNIMED has developed several bone cements currently used in vertebroplasty and kyphoplasty procedures in the treatment of vertebral weakness. Among those, one cement is also used in pedicle screw augmentation procedures.

With the increasing use of these procedures, there is a need of real-life safety and efficacy data on the bone cements.

This retro-prospective study is performed to confirm the safety and performance of TEKNIMED spine bone cements in their current clinical use.

02

Conditions studied

  • Vertebral Fracture
  • Compression Fracture
  • Osteoporotic Fractures
03

In context

Spinal Fractures

144 studies on the registry are indexed under Spinal Fractures; 24 are open to participants now.

This study's planned enrollment of 500 is above the median of 93 across 55 observational studies indexed under Spinal Fractures.

Browse Spinal Fractures studies →

Lead sponsor

Teknimed is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients suffering from painful vertebral compression fractures resulting from osteoporosis, benign or malignant lesions, or of traumatic origin

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18 years or older
  • Be willing to sign an approved by Ethic Committee (when applicable) or not being opposed to the use of their clinical data in the study

    o For prospective inclusion:

  • Be considered for treatment with one of the TEKNIMED Spine Range cement comprised in this study

    o For retrospective inclusion:

  • Have undergone a surgery with a TEKNIMED Spine Range cement between the 1st of January 2016 and the date of the site initiation visit.
  • Be informed of the study and not being opposed to the use of their clinical data in the study or be willing to sign an informed consent during the first follow-up visit following the site initiation (when applicable).

Exclusion criteria

Exclusion Criteria:

Patients presenting one of the following conditions will not be included ( per IFU):

  • Procedures other than those stated in the INDICATIONS section
  • Coagulation disorders, or severe cardiopulmonary disease
  • Unstable vertebral fractures
  • Compromise of the vertebral body or of the pedicle walls
  • or allergy to one of the constituents of the product
  • Patient clearly improving on more conservative treatment
  • Prophylactic use in spinal or osteoporotic patients with no evidence of acute fracture
  • Paediatric patients and pregnant or breast-feeding women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • F20 VP

    Vertebroplasty

    Device: Vertebroplasty (VP)

  • F20 KP

    Kyphoplasty

    Device: Kyphoplasty (KP)

  • SPINEFIX VP

    Vertebroplasty

    Device: Vertebroplasty (VP)

  • SPINEFIX KP

    Kyphoplasty

    Device: Kyphoplasty (KP)

  • SPINEFIX PSA

    Pedicular Screw Augmentation

    Device: Pedicular Screw Augmentation (PSA)

  • HIGH V+ VP

    Vertebroplasty

    Device: Vertebroplasty (VP)

  • HIGH V+ KP

    Kyphoplasty

    Device: Kyphoplasty (KP)

  • OPACITY+ VP

    Vertebroplasty

    Device: Vertebroplasty (VP)

  • OPACITY+ KP

    Kyphoplasty

    Device: Kyphoplasty (KP)

Interventions

  • DeviceVertebroplasty (VP)

    Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

  • DeviceKyphoplasty (KP)

    Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

  • DevicePedicular Screw Augmentation (PSA)

    Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength

06

What researchers measure

Primary outcomes

  1. Alleviation of Pain

    Pain evaluated by Visual Analogue Scale (VAS): on a scale of 0 to 10, with 0 being no pain and 10 being the most severe pain at the Baseline and at the Follow-up visits

    Time frame: 24 months

Secondary outcomes

  1. Restoration of quality of life

    Evaluated through short questions : Oswestry Disability Index (ODI score)

    Time frame: 24 months

  2. Patient satisfaction

    Evaluated through short questions : A. Are you satisfied with your surgery? Yes/No/Without opinion B. Has your health improved? Yes/Stable/No C. Given the results, would you accept this intervention again? Yes/No/Without opinion

    Time frame: 24 months

  3. Stabilization of vertebrae

    Radiographic imaging

    Time frame: 24 months

  4. Adverse events

    All adverse events occured during surgery and through study completion

    Time frame: 10 years

  5. Antalgic Consumption

    Antalgic consumption and the drug type at the Baseline and at the Follow-up visits

    Time frame: 24 months

07

Study locations

12 of 12 sites recruiting
  • CHU HautePierre
    Strasbourg, Bas-Rhin 67200, France
    Recruiting
  • Pôle Rachis Hôpital Privé d'Eure et Loir
    Mainvilliers, Eure et Loir 28300, France
    Recruiting
  • Hôpital Toulouse Purpan
    Toulouse, Haute Garonne 31130, France
    Recruiting
  • Pôle Sud Santé
    Le Mans, Sarthe 72100, France
    Recruiting
  • Centre Hospitalier Métropole Savoie
    Chambéry, Savoie 73000, France
    Recruiting
  • Hospitale Cruz Vermelha Portuguesa
    Lisbon, 1549-008, Portugal
    Recruiting
  • Clínica Teknon Instituto de neurociencias
    Barcelona, 08022, Spain
    Recruiting
    • Daniel CRUZ MIRANDA, MD · Contactdr.jdcruz@gmail.com
    • David BOSCH GARCIA, MD · Principal investigator
  • Hospital Neurotraumatologico
    Granada, 18013, Spain
    Recruiting
    • Fernando RUIZ SANTIAGO, MD · Contactferusan12@gmail.com
    • Fernando RUIZ SANTIAGO, MD · Principal investigator
  • Hospital Clínico Universitario Virgen de la Arrixaca
    Murcia, 30120, Spain
    Recruiting
    • Gonzalo DE PACO TUDELA, MD · Contactgonzalodepaco@gmail.com
    • Gonzalo DE PACO TUDELA, MD · Principal investigator
  • Fundacio Assistencial Mutua de Terrassa - Edifici Estació
    Terrassa, 08222, Spain
    Recruiting
  • Hospital de Zafra
    Zafra, 06300, Spain
    Recruiting
  • Institute of Traumatology and Orthopaedics
    Kiev, 1601, Ukraine
    Recruiting
    • Andrii SHEVCHUK, MD · Contactfasti@i.ua
    • Andrii SHEVCHUK, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06367582
Lead sponsor
Teknimed
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Sep 4, 2019
Primary completion
Sep 4, 2029 (estimated)
Completion
Sep 30, 2039 (estimated)
Last update
Sep 9, 2025

Study contacts

Solange VAN DE MOORTELE, PhD
Contact
s.vandemoortele@teknimed.com
+33534252679

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion